Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma

Japanese Journal of Clinical Oncology

Volumn 44, Issue 6, 2014, Pages 570-578

  Takahashi, Hiroyuki ^a,b   Ojima, Hidenori ^a   Shimizu, Hiroko ^a   Furuse, Junji ^c   Furukawa, Hiroyuki ^b   Shibata, Tatsuhiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Axitinib; Cholangiocarcinoma; VEGFR TKI; Xenograft model

Indexed keywords

AXITINIB; CD31 ANTIGEN; GEMCITABINE; KI 67 ANTIGEN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CAPILLARY DENSITY; CHOLANGIOCARCINOMA CELL LINE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

AXITINIB; CHOLANGIOCARCINOMA; VEGFR-TKI; XENOGRAFT MODEL;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; GENE EXPRESSION PROFILING; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INDAZOLES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901771474     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyu045     Document Type: Article

References (43)

1. Mouzas IA, Dimoulios P, Vlachonikolis IG, et al. Increasing incidence of cholangiocarcinoma in Crete 1992-2000. Anticancer Res 2002; 22:3637-41.
2. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002;17:1049-55.
3. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet 2005;366:1303-14.
4. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48:308-21.
5. Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008;42:178-90.
6. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008;13:415-23.
7. Aljiffry M, Abdulelah A, Walsh M, et al. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 2009;208:134-47.
8. Berthiaume EP,Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004;24:127-37.
9. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005;41:5-15.
10. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005;16(Suppl 2):ii93-6.
11. Ieta K, Tanaka F, Utsunomiya T, et al. CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer 2006;95:532-40.
12. Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:2332-8.
13. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010;103:469-74.
14. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81.
15. Hanahan D,Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
16. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000;21:505-15.
17. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-70.
18. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
19. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) breast cancer study group. J Clin Oncol 1992;10:1049-56.
20. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001;8:72-9.
21. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):S9-15.
22. Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006;94:1823-32.
23. Mohammed RA, Green A, El Shikh S, et al. Prognostic significance of vascular endothelial cell growth factors-A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 2007;96:1092-100.
24. Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008;98:418-25.
25. Ojima H, Yoshikawa D, Ino Y, et al. Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer Sci 2010;101:882-8.
26. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272-83.
27. Rossler J, Monnet Y, Farace F, et al. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. Int J Cancer 2010;128:2748-58.
28. Tang D, Nagano H, Yamamoto H, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 2006;15:525-32.
29. Yoshikawa D, Ojima H, Kokubu A, et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 2009;100:1257-66.
30. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
31. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
32. Schmidinger M, Arnold D, Szczylik C, et al. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 2010;28:856-64.
33. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011;378:1931-9.
34. Patson B, Cohen R, Olszanski AJ. Pharmacokinetic evaluation of axitinib. Expert Opin Drug Metab Toxicol 2012;8:259-70.
35. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13.
36. Spano JP, Chodkiewicz C,Maurel J, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer:an open-label randomized phase II study. Lancet 2008;371:2101-8.
37. Schiller JH, Larson T, Ou SH, et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009;27:3836-41.
38. Fruehauf J, Lutzky J, McDermott D, et al. Multicenter, phase ii study of axitinib, a selective second-generation inhibitor of vascular endothelialgrowth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 2011;17:7462-9.
39. Rugo HS, Stopeck AT, Joy AA, et al. Randomised, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011;29:2459-65.
40. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8.
41. Endo M, Nakano M, Kadomatsu T, et al. Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. Cancer Res 2012;72:1784-94.
42. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
43. Bendell JC, Tournigand C, Bednarczyk M, et al. Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) [abstracts 29]. In: ASCO Meeting 2011, p. 478.